Latest Production Development News

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

Dexus launches the Dexus Strategic Investment Trust series, acquiring a 25% stake in Westfield Chermside and raising $390 million for its DREP2 fund, while legal mediation is pushed to March 2026.

Spenda Limited has successfully raised $1.4 million through a private placement, attracting both new and existing sophisticated investors to support its product development and working capital needs.

Wisr Limited has successfully closed its Share Purchase Plan, raising $1.22 million and reducing corporate debt by $7.5 million as part of a broader $10.6 million capital raise.

Premier Investments reported a robust FY25 with a 31% rise in net profit, driven by strong performances from Peter Alexander and Smiggle, alongside a strategic capital return plan including a $100 million share buyback.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Biotron Limited has completed a $1 million placement to fund the development of its newly acquired Sedarex Limited assets, marking a strategic expansion of its antiviral portfolio.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.